Background: Recent guidelines advocate unilateral thyroidectomy for low-risk 1-cm to 4-cm differentiated thyroid cancer (DTC). This study was designed to examine the association between the extent of thyroidectomy and oncologic outcomes in patients with 1-cm to 4-cm DTC. Materials and Methods: From April 1978 to December 2011, 16 057 patients with DTC underwent thyroidectomy at Yonsei University Hospital. Among them, 5266 (32.8%) patients were classified as having 1-cm to 4-cm DTC and were enrolled in this study. Clinicopathologic features and prognostic results (diseasefree survival [DFS] and disease-specific survival [DSS] rates) were analyzed by retrospective medical record review. The mean follow-up duration was 57.3 ± 58.1 months. Results: Of tumor subtypes in the study group, papillary thyroid carcinoma was the most common (97.5%) and follicular thyroid carcinoma occurred at a rate of 2.5%. In this study, the mean tumor size was 1.84 ± 0.74 cm. Patients had extrathyroidal extension (69.3%), multiplicity (35.1%), bilaterality (26.4%), central lymph node metastasis (53.0%), and lateral neck node metastases (19.9%). Of the 5266 patients, 4292 (81.5%) underwent total thyroidectomy and 974 (18.5%) had lobectomies. Recurrence rates in the total thyroidectomy and lobectomy groups were 5.7% and 9.4%, respectively. The lobectomy group had lower DFS (P = .007) and higher DSS (P = .034) than the total thyroidectomy group. A multivariate analysis for DFS revealed that tumor size, N classification, and extent of thyroidectomy were independent risk factors. On multivariate analysis, independent risk factors for DSS were age, sex, tumor size, and M classifications. Conclusion: Although extent of thyroidectomy does not affect DSS, total thyroidectomy is beneficial for reducing recurrence in patients with 1-cm to 4-cm DTC. However, if such tumors have such low-risk features as being unifocal, intrathyroidal, and lymph node metastasis-negative, extent of thyroidectomy does not affect oncologic outcome and lobectomy may be sufficient.
| INTRODUCTION
Thyroid cancer is the most common endocrine malignancy with an incidence of 1.4 per 100 000 people in the United States in 2011. 1 In Korea, the incidence of thyroid cancer has been rapidly increasing and the incidence rate for thyroid cancer in 2011 was 15 times that observed in 1993. Fortunately the biologic behavior of DTC enables high long-term survival rates after treatment. The extent of surgery for DTC based on tumor size has been debated for several decades, especially for patients at low risk (unifocal, intrathyroidal, and N0 classification). Total thyroidectomy (TT) has traditionally been advocated for thyroid cancers >1 cm. 2, 3 However, recent American Thyroid Association guidelines, 4 citing recent studies that failed to demonstrate an association between extent of surgery for DTC and survival, 5, 6 recommend that patients with high-risk tumors undergo total or near-total thyroidectomy and persons with low-risk DTC ≤4 cm have less extensive surgery such as lobectomy. Until now, no large-scale studies have been conducted in Korea on surgical outcome of patients with 1-cm to 4-cm DTC. Thus, the first purpose of this study was to evaluate the clinicopathologic features, oncologic outcome, and prognostic factors of patients with 1-cm to 4-cm DTC based on surgical extent. The second purpose was to identify the prevalence of low-risk 1-cm to 4-cm DTC and compare oncologic outcomes in relation to surgical extent and risk groups.
| MATERIALS AND METHODS

| Patients
This was a retrospective study using data collected prospectively by use of the endocrine surgery database at Yonsei University College of Medicine. [] This study was approved by the university's institutional review board (IRB No: 4-2016-0954). We reviewed the medical records of 16 057 consecutive patients with thyroid cancer who underwent initial surgery in our department between April 1978 and December 2011. Of those, we identified 5266 patients with 1-cm to 4-cm DTC: 5136 (97.5%) had papillary thyroid cancer (PTC) and 130 (2.5%) had follicular thyroid cancer (FTC). All patients in the study cohort had been followed ≥5 years. The mean follow-up period was 57.3 ± 58.1 months. Tumor sizes were measured from surgical specimens.
| Surgical strategy and postoperative follow-up
Of the patients, 4292 (81.5%) underwent TT and 974 (18.5%) had ipsilateral lobectomy. Total thyroidectomy was performed if preoperative evaluation revealed clinically bilateral and multifocal DTC, definite extrathyroidal invasion, evidence of clinical lymph nodelymph node involvement, and/or distant metastases, and personal history of radiotherapy to the head and neck. Multicentricity was assessed with preoperative ultrasonography and final pathologic results. We did not evaluate multicentricity intraoperatively with frozen section. In this study, both gross and microscopic extrathyroidal extension (ETE) were included in ETE. We evaluated ETE with final pathology and could not classify ETE as gross or microscopic. In all cases, prophylactic ipsilateral central compartment neck dissection, including prelaryngeal, pretracheal, and paratracheal lymph node, was performed for accurate classification and management of subclinical lymph node metastasis. Clinically positive central lymph node metastasis was defined as status with signs of enlarged lymph node involvement during preoperative ultrasonography or palpated lymph node involvement during preoperative physical examination. In the TT group, 468 (10.9%) patients had clinically positive central lymph node involvement. But in the lobectomy group, no patients had clinically positive central lymph node involvement and all of them had microscopic positive central lymph node involvement. Whenever lateral lymph node involvement was suspected during preoperative ultrasonography, the diagnosis was always confirmed by histologic examination from fine-needle aspiration cytology. When the result was positive, we performed therapeutic modified radical neck dissection. Therefore, all patients with lateral lymph node metastasis had clinically N1 disease. If the final pathologic results were aggressive subtypes, such as tall cell or diffuse sclerosing variant carcinoma, completion TT was performed. Those patients were considered to have undergone TT. However, if the pathologic features were equivocal, with risk factors such as an incidental multifocal lesion, minimal capsular invasion, or micrometastatic central lymph node invasion, completion TT was not performed.
After surgery, all patients were treated with levothyroxine (LT 4 ) to suppress thyroid-stimulating hormone. Of the patients who underwent TT, 3981 patients (75.5%) who satisfied indications underwent radioactive iodine (RAI) therapy. In all, 3095 patients (58.7%) were treated with low-dose RAI (30 mCi) and 886 (16.7%) were treated with high-dose RAI (100-200 mCi) (Table 1) ; the RAI dose depended on the metastatic and residual diseases suspected or documented. We regularly followed all patients by neck ultrasonography and serum thyroglobulin testing at 6-month or 12-month intervals to seek local recurrences. Each patient also had either an annual chest radiograph or a computed tomography scan to detect potential lung metastases. Whenever a recurrence in the remnant thyroid, resection bed, or lymph node was suspected, the diagnosis was confirmed by histologic examination from aspiration cytology or reoperation.
| Outcome assessment
The cohort was categorized into two groups based on the extent of surgery: patients who underwent lobectomy and patients who underwent TT. The two groups were compared with respect to demographic and pathologic findings, DFS, and DSS. We excluded patients with distant metastasis in DFS and DSS analysis.
To calculate DFS and DSS stratified by group pathologic characteristics, each group (TT vs lobectomy) was divided into 2 subgroups (low-risk or high-risk) based on the final pathology. The high-risk group was defined as having any one of the following features: aggressive histology (tall cell, diffuse sclerosing variant), bilateral or multifocal lesion, ETE, lymph node involvement, and/or distant metastasis.
| Statistical analysis
Data were expressed as mean ± SD) or n (%) for descriptive statistics. All data were analyzed with IBM SPSS statistics software (version 23.0; SPSS Inc., Chicago IL, United States). A t test was used for continuous variables. The Pearson product moment correlation chi-square test and Fisher exact test were used for categorical variables. Kaplan-Meier survival analysis was used to estimate DFS and DSS.
The Cox proportional hazard (Cox PH) regression model was used for the identification of prognostic factors for DFS and DSS. In all cases, a P value <.05 was considered statistically significant.
| RESULTS
| Patient characteristics
We analyzed data for 5266 DTC patients who underwent thyroidectomy between April 1978 and December 2011. The mean age of the cohort was 45.41 ± 12.10; 4462 (84.7%) Table 1 . The TT group was older than the lobectomy group (45.06 ± 12.77 vs 43.23 ± 14.03 years; P = .002) and had a greater proportion of men (16.7% vs 8.6%; P = .0000). Mean tumor size was also significantly larger in the TT group (1.93 ± 0.81 vs 1.60 ± 0.56 cm; P = .000).
The TT group demonstrated significantly more aggressive pathologic findings than the lobectomy group in terms of multicentricity (39.6% vs 15.6%; P = .003), bilaterality (31.3% vs 5.3%; P = .0000), ETE (74.6% vs 46.3%; P = .0000), central lymph node metastasis (57.6% vs 32.3%; P = .0000), lymph node metastasis (24.5% vs 0%; P = .0000), and TNM classification classification I 51.9% vs 75.6%, classification II 1.1% vs 2.7%, classification III 32.8% vs 21.5%, andclassification IV 14.1% vs 0%; P = .0000).
| Prognostic and surgical outcomes
During follow-up, the recurrence rate was significantly higher in the lobectomy group than in the TT group (9.4% vs 5.7%; P = .001). However, there was no statistically significant difference in the mortality rate between the 2 groups (0.98% vs 0.60%; P = .603) ( Table 1) .
There were no distant metastases identified in the lobectomy group. Time to recurrence was significantly longer in the lobectomy group than in the TT group (90.66 ± 59.89 vs 63.80 ± 27.36 months; P = .001). Most common sites of locoregional recurrence in the lobectomy and TT groups were the contralateral lobe (8.7%) and lateral neck lymph node (4.3%), respectively. Interestingly, there were no central lymph node metastases identified in the lobectomy group ( Table 2) .
The DFS and DSS were compared between the 2 groups. The DFS was lower in the lobectomy group than in the TT group (P = .026). The 10-year DFS rates were similar between the groups (92.4% vs 93.8%, lobectomy and TT, respectively), but the 25-year DFS rates were significantly different between the lobectomy and TT groups (83.6% vs 89.0%) (P = .026) (Figure 1) . DSS was significantly lower in the TT group than in the lobectomy group (P = .004). Twenty-five-year DSS was 99.6% in the TT group and 100% in the lobectomy group (P = .004) (Figure 2) .
On univariate analysis for DFS, tumor size, ETE, nodal stage, and extent of thyroidectomy were prognostic factors. However, multivariate analysis revealed that tumor size (odds ratio [OR], 2.246; 95% CI 1.769-2.851; P < .001), 
| Prevalence of low-risk groups and surgical outcomes by risk group
Of the 5266 patients, only 47 (0.89%) were included in the low-risk group as classified by unifocal lesion, no lymph node invasion, and no ETE. Thirty-one (66%) had PTC including 29 with classical type and 2 with follicular variant. The remaining 16 (34%) patients had minimally invasive FTC (Supplement 1).
In the low-risk group, 20 (42.5%) underwent TT and 27 (57.4%) had ipsilateral lobectomy. Although our sample papulations with low-risk tumors were small, there were almost equivalent numbers in each group. Recurrence rates in the TT and lobectomy groups with low-risk patients were 10.0% and 7.4%, respectively, but there was no significant difference between the 2 groups (P = .683) (Supplement 2).
The DFS and DSS were compared according to risk group stratified by surgery extent (Figure 3 ). In the low-risk group, DFS was significantly lower in the TT group than in the lobectomy group (P = .024). However, DSS was similar (P = .583). In the high-and intermediate-risk groups, patients who had lobectomies had lower DFS (P = .001) and higher DSS (P = .046) than those in the TT group.
| DISCUSSION
Recent consensus guidelines suggest that patients with highrisk 1-cm to 4-cm tumors should undergo total or near-total FIGURE 2 Disease-specific survival (DSS) of patients who underwent thyroidectomy for 1-cm to 4-cm differentiated thyroid carcinoma by extent of thyroidectomy DSS was slightly lower in the TT group than in the lobectomy group. The 25-year DSS was 99.6% in the TT group and 100% in the lobectomy group (p = .004) [Color figure can be viewed at wileyonlinelibrary.com] Abbreviations: CI, confidence interval; OR, odds ratio. Abbreviation: CI, confidence interval; OR, odds ratio.
FIGURE 3 Disease-free (DFS) and disease-specific survival (DSS) according to risk groups stratified by extent of thyroidectomy of 1-cm to 4-cm differentiated thyroid carcinoma. In the low-risk group, DFS was significantly lower in the TT group than in the lobectomy group (P = .024). However, DSS was similar (p = .583). In the high-risk and intermediate-risk groups, patients who had lobectomies had lower DFS (p = .001) and higher DSS (p = .046) than those in the TT group [Color figure can be viewed at wileyonlinelibrary.com] thyroidectomy, and that patients with unifocal, small, intrathyroidal, or lymph node-negative DTC (so-called lowrisk featured tumors) can undergo less extensive surgeries such as lobectomies. 4, 7, 8 Previous studies found that causespecific survival and overall survival were not affected by extent of thyroidectomy. 5, [9] [10] [11] [12] [13] [14] [15] [16] [17] In contrast, Barney et al 9 reported that TT resulted in improved survival when compared with near-total thyroidectomy. However, they pointed out that despite this well-powered large cohort study, the clinical difference seemed insignificant. The absolute differences in 10-year overall survival and cause-specific survival estimates were only 0.9% and 0.2%, respectively, favoring total thyroidectomy in appropriately matched subjects. In addition, potential complications of more aggressive operations were given much more weight against the slight survival differences seen in some studies. 18, 19 Recent consensus guidelines reflect these findings as well as statistical observations. 4 In this study, our objective was to compare surgical outcomes according to extent of thyroidectomy in patients with 1-cm to 4-cm DTC. Bilimoria et al 3 reported that TT resulted in lower recurrence rates for PTC when tumors were ≥1.0 cm in diameter (P = .04). We found that there were higher recurrence rates in patients with lobectomy than in those with TT (9.4% vs 5.7%; P = .001) and that DFS was lower in the lobectomy group (P = .007). These findings are consistent with findings from a previous study. Furthermore, our multivariate analysis also showed that extent of thyroidectomy was an independent risk factor for DFS (OR, 0.420; P < .001). Therefore, in our study TT reduced recurrence rates in patients with 1.0-cm to 4.0-cm DTC, which we attribute to removal of foci from the contralateral lobe. The DSS was lower in the TT than in the lobectomy group for patients with 1-cm to 4-cm DTC (P = .034). Possibly these results can be explained by the fact that those undergoing TT had more high-risk factors associated with lower DSS such as old age, large tumor size, and male sex than those undergoing lobectomy. However, multivariate analysis showed that extent of thyroidectomy was not an independent risk factor for DSS. Therefore, we conclude that DSS is not affected by extent of thyroidectomy in patients with 1-cm to 4-cm DTC. This is consistent with findings in several other studies that reported that CSS and OS are not affected by surgical extent in DTC. 5, [9] [10] [11] [12] [13] [14] [15] [16] [17] In the current study, tumor size was an independent risk factor for both DFS and DSS. In subset classification based on tumor size, 2-cm to 4-cm DTC (T2) had higher risk for both recurrence (OR, 2.246; 95% CI 1.769-2.851; P < .001) and disease-related death (OR, 2.497; 95% CI 1.317-4.734; P = .005) than 1-cm to 2-cm DTC (T1). Therefore, exact preoperative measurement of tumors is important for surgical outcomes in patients with 1-cm to 4-cm DTC and should be used to determine extent of thyroidectomy. In our data, tumor size is based on the final pathologic report. Sometimes it does not reflect the preoperative tumor size because formalin fixation may cause tumor shrinkage. However, we assumed that this shrinkage is minimal and it does not affect the clinical outcomes significantly. Furthermore, our main opinion about tumor size is that we should try to measure exact tumor size preoperatively on the tumors lying at the T1 and T2 boundaries, which might show different prognosis.
Recent guidelines recommend bilateral or unilateral procedures for patients with 1-cm to 4-cm DTC, no ETE, and no clinical evidence of lymph node metastasis. 4 In this study, just 0.89% of patients did not have multifocal, ETE, and clinical evidence of lymph node metastasis. Two earlier studies also evaluated an association between tumor size and lymph node metastasis. 20, 21 Suman et al 20 found that tumors ≥1.0 cm were independent risk factors for central lymph node metastasis with propensity score-matched prophylactic CCND patients, and Jeong et al reported that patients with lymph node metastases had larger tumors than those without lymph node metastases (1.59 ± 1.03 vs 0.93 ± 0.62 cm; P < .001). 21 On the basis of these findings, we expected patients with 1-cm to 4-cm DTC to be more likely to have central lymph node metastasis (including occult central lymph node metaqstasis) and less likely to have low-risk featured tumors than those with smaller DTC tumors. In fact, these findings are consistent with our study results (0.89%). It is important to consider the study by Kluijfhout et al, 22 who
found that 43% of patients undergoing thyroid lobectomy for preoperatively low-risk 1-cm to 4-cm DTC would have needed completion TT after initial lobe pathologic analysis based on findings regarding ETE (17%), incidental positive lymph node metastasis (18%), and multicentricity (25%). Thus, clinicians must recognize that many patients with preoperatively low-risk 1-cm to 4-cm DTC have high-risk characteristics that are only confirmed by final pathology. Our study showed that low-risk patients with lobectomies had higher DFS than TT patients (P = .024) and no significant difference in DSS stratified by the extent of thyroidectomy (Figure 3a,b) . Matsuzu et al 12 found that remnant thyroid recurrence-freesurvival, regional lymph node recurrence-free survival, and distant recurrence-free survival rates 25 years after surgery were 93.5%, 90.6%, and 93.6%, respectively, in 1088 patients who underwent thyroid lobectomy for low-risk PTC ≤4.0 cm, and that patients treated by lobectomy had excellent long-term clinical outcomes. We had similar findings: The lobectomy group had longer DFS than patients receiving TT. Kim et al 23 also reported no significant impact of surgical extent on recurrence of low-risk PTC tumors ≤4 cm on multivariate analysis (P = .776). Thus, on the basis of our results and those of others we conclude that extent of thyroidectomy does not affect surgical outcomes in low-risk patients with 1-cm to 4-cm DTC. This study has limitations due to its retrospective nature. The primary limitation was selection bias because all study participants were from one high-volume tertiary institution where they had initial therapy and follow-up regimens.
Second, our sample populations with low-risk tumors were too small to predict outcomes in the general population. Further research with large and long-term follow-up populations with low-risk tumors is needed to determine the most valid indicators for extent of thyroidectomy. Third, molecular status, such as BRAF and TERT mutation (which can be associated with prognosis), was not considered in this study. We could not check BRAF mutation status routinely until 2014. Since 2014, we routinely check BRAF mutation status for PTC and plan to conduct further research on the associations between the status of gene mutation and the prognosis of 1-cm to 4-cm DTC. Fourth, because many of the study data predate the use of high-resolution ultrasonography in our institution, the lobectomy group included a small portion of the patients who had thyroid cancers with bilaterality, ETE, and central lymph node metastasis at the time of final pathology. Before 2001, when high-resolution ultrasonography was introduced, the lobectomy group included a few patients who had thyroid cancers with multiplicity (6.5%), bilaterality (2.2%), ETE (21.7%), and central lymph node metastasis (13.5%). Since 2001, when high-resolution ultrasound was introduced, our indications for thyroidectomy have followed American Thyroid Association guidelines. 2 We conclude that although extent of thyroidectomy does not affect DSS, TT is beneficial for reducing recurrences in patients with 1-cm to 4-cm DTC. However, if such tumors have low-risk features such as being unifocal, intrathyroidal, and lymph node-negative, the extent of thyroidectomy does not affect oncologic outcome and lobectomy may be sufficient.
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